Table 1 Patient characteristics

From: Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

 

N

%

Median

Range

Age at study entry

  

51

(15–76)

Gender

 Male

9

18

  

 Female

41

82

  

Tumour type

 Breast adenocarcinoma

20

40

  

 Sarcoma

19

38

  

 Melanoma

6

12

  

 Ovarian adenocarcinoma

2

4

  

 Colorectal adenocarcinoma

1

2

  

 Pancreatic adenocarcinoma

1

2

  

 Non-small cell lung cancer

1

2

  

Prior lines of chemotherapy/MTA

  

3

(0–8)

Type of last treatment received

 Chemotherapy±MTA

32

64

  

 MTA

5

10

  

 Hormone therapy

3

6

  

 None

10

20

  
  1. Abbreviation: MTA=molecularly targeted agent.